Evidence map›Paper›PMID 34489263›Full record

ArticleBMJ open2021

Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO.

Beverley Stringer, Karen Lowton, Nicola James, Bern-Thomas Nyang'wa

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03942354 (Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03942354 completednot on this map

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

TypeobservationalSponsorMedecins Sans Frontieres, NetherlandsRan2019 to 2022Enrolled137ConditionsMultidrug Resistant TuberculosisArmsBedaquiline, Pretomanid, Moxifloxacin, Linezolid, Clofazimine
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Beverley StringerManson Unit, Médecins Sans Frontières, London, UK beverley.stringer@london.msf.org.ORCID 0000-0003-1859-6650
Karen LowtonDepartment of Sociology, University of Sussex, Brighton, UK.
Nicola JamesManson Unit, Médecins Sans Frontières, London, UK.ORCID 0000-0002-1269-9811
Bern-Thomas Nyang'waManson Unit, Médecins Sans Frontières, London, UK.ORCID 0000-0001-9915-5878
Médecins Sans Frontières‎ · GBLondon School of Hygiene & Tropical Medicine · GBUniversity of Sussex · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPeople living with multidrug-resistant tuberculosis currently have few options for effective treatment and cure. Regimens that are available are toxic, may involve injections and take up to 2 years to complete treatment, with success rates as low as 50%. The TB-PRACTECAL trial is evaluating shorter, more tolerable regimens of oral drugs; we detail the substudy within this trial, PRACTECAL-PRO, which aims to evaluate patient experiences and perspectives on treatment, to understand outcomes more fully. METHODS AND ANALYSIS: We are conducting a mixed-methods evaluation within both investigational and standard of care arms within the TB-PRACTECAL trial, using sequential quality of life (QoL) surveys and in-depth interviews. Data collection involves the Short Form 12 (SF-12) and St George's Respiratory Questionnaire (SGRQ), collected at up to four fixed timepoints, from baseline, to up to 12 months later. Healthy volunteers will be surveyed to establish locally relevant controls. We will also purposively sample participants for qualitative data collection and analysis, to provide rich explanation of QoL scores. The study will be implemented in all six TB-PRACTECAL study sites in Uzbekistan, South Africa and Belarus. QoL surveys will be scored and analysed according to SF-12 and SGRQ developers' manuals. Differences between scores at baseline and later timepoints will be evaluated as well as graphical exploration of group score trajectories of investigational and standard of care arms. ETHICS AND DISSEMINATION: Ethics approval was obtained from the Médecins Sans Frontières Ethics Review Board. Local ethics approval has been obtained in Uzbekistan, Belarus and South Africa. Results of the substudy will be shared with local health authorities, the WHO and submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT03942354; Pre-results.

Indexed as

Quality of LifeTuberculosis, Multidrug-ResistantAntitubercular AgentsClinical ProtocolsHumansPatient Reported Outcome MeasuresAntitubercular Agentsclinical trialsqualitative researchtuberculosis

Identifiers

PMID34489263
PMCPMC8422308
OpenAlexW3196909390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.